Literature DB >> 19752330

Combined hormone therapy at menopause and breast cancer: a warning--short-term use increases risk.

Leslie Bernstein.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19752330      PMCID： PMC4818288          DOI： 10.1200/JCO.2009.23.9988

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  36 in total

Review 1.  Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy.

Authors: 
Journal:  Menopause       Date:  2003 Jan-Feb       Impact factor: 2.953

Review 2.  Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society.

Authors: 
Journal:  Menopause       Date:  2004 Nov-Dec       Impact factor: 2.953

Review 3.  Estrogen and progestogen therapy in postmenopausal women.

Authors: 
Journal:  Fertil Steril       Date:  2008-11       Impact factor: 7.329

4.  Racial differences in breast cancer trends in the United States (2000-2004).

Authors:  Ruth M Pfeiffer; Aya Mitani; Rayna K Matsuno; William F Anderson
Journal:  J Natl Cancer Inst       Date:  2008-05-13       Impact factor: 13.506

5.  Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003.

Authors:  Esther Hing; Kate M Brett
Journal:  Obstet Gynecol       Date:  2006-07       Impact factor: 7.661

6.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

Review 7.  Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought.

Authors:  Leon Speroff
Journal:  Menopause       Date:  2008 Mar-Apr       Impact factor: 2.953

8.  Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.

Authors:  Ross L Prentice; Rowan T Chlebowski; Marcia L Stefanick; Joann E Manson; Mary Pettinger; Susan L Hendrix; F Allan Hubbell; Charles Kooperberg; Lewis H Kuller; Dorothy S Lane; Anne McTiernan; Mary Jo O'Sullivan; Jacques E Rossouw; Garnet L Anderson
Journal:  Am J Epidemiol       Date:  2008-03-27       Impact factor: 4.897

9.  The decrease in breast-cancer incidence in 2003 in the United States.

Authors:  Peter M Ravdin; Kathleen A Cronin; Nadia Howlader; Christine D Berg; Rowan T Chlebowski; Eric J Feuer; Brenda K Edwards; Donald A Berry
Journal:  N Engl J Med       Date:  2007-04-19       Impact factor: 91.245

10.  Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.

Authors:  Ross L Prentice; Joann E Manson; Robert D Langer; Garnet L Anderson; Mary Pettinger; Rebecca D Jackson; Karen C Johnson; Lewis H Kuller; Dorothy S Lane; Jean Wactawski-Wende; Robert Brzyski; Matthew Allison; Judith Ockene; Gloria Sarto; Jacques E Rossouw
Journal:  Am J Epidemiol       Date:  2009-05-25       Impact factor: 4.897
View more
  1 in total

1.  Oral contraceptives, menopausal hormone therapy use and risk of B-cell non-Hodgkin lymphoma in the California Teachers Study.

Authors:  Yani Lu; Sophia S Wang; Jane Sullivan-Halley; Ellen T Chang; Christina A Clarke; Katherine D Henderson; Huiyan Ma; Lei Duan; James V Lacey; Dennis Deapen; Leslie Bernstein
Journal:  Int J Cancer       Date:  2010-12-08       Impact factor: 7.396
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.